Kala Bio announced that CHASE (NCT05727878), its phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect ...
Explore the Fight Retinal Blindness! Project, a global registry enhancing VEGF inhibitor treatment outcomes with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback